Drugs / CG-P5
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06132035 | Dec 2023 → May 2025 overdue | wet macular degeneration | Caregen Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG-P5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06132035 ↗ |
| Modality | Peptide | “CG-P5 peptide eye drops” NCT06132035 ↗ |
| Route | Topical | “CG-P5 Peptide Eye Drops (Self-administered and Topically Applied)” NCT06132035 ↗ |